Natriumoxybat Ascend (Sodium Oxybate)

Sodium oxybate acts as an agonist at GABA_B receptors in the central nervous system. By enhancing inhibitory GABAergic signaling, it modifies sleep architecture, promoting deeper, more restorative nocturnal sleep and consequently decreasing daytime sleepiness and cataplexy episodes.

The specific dose of Natriumoxybat Ascend is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and tolerability. Dosage adjustments are made during treatment to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for sodium oxybate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Sodium oxybate is the only medication approved specifically for cataplexy and excessive daytime sleepiness in narcolepsy, offering a unique mechanism via GABA_B receptor activation. Other agents, such as modafinil or pitolisant, primarily target wakefulness and do not address cataplexy, making sodium oxybate a distinct therapeutic option.

Natriumoxybat Ascend should be stored at temperatures below 25 °C. Keep the oral solution in its original container, protect it from moisture and direct light, and ensure the cap is tightly closed to maintain stability.

The medication is supplied as an oral solution that is taken by mouth. It is usually divided into multiple doses taken at night, as directed by the prescribing physician, to align with the patient’s sleep schedule.

Serious risks include respiratory depression, severe hypotension, seizures, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely, especially during dose initiation and when combined with other central nervous system depressants.

Individuals with known hypersensitivity to sodium oxybate, severe renal impairment, or those who consume alcohol or other CNS depressants should not use this medication. Additionally, patients with untreated sleep‑disordered breathing should avoid it until evaluated by a specialist.